• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Lessons from the left heart in developing novel therapeutic options for right heart failure in pulmonary arterial hypertension

    1Nayan Kumar Patel, 2Rekha Manjhi, 3Sudarsan Pothal, 4Narendra, 5Pravati Dutta, 6Aurobindo Behera .

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 3309-3325

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

In pulmonary arterial hypertension, right heart function is the most important indicator of prognosis (PAH). As we will show in this post, there are currently no medicines available that directly target the right ventricle.
When analysed using the pump-function graph, a meta-analysis of clinical trials in PAH found that current PAH treatment appears to have minimal cardiac-specific effects. We investigated the clinical potential of left heart failure (LHF) therapy for PAH based on currently available data, driven by the idea that "left" and "right" heart failure may share fundamental underlying pathophysiological mechanisms.
The sympathetic nervous system and the renin–angiotension–aldosterone system are both significantly active in PAH, just as they are in LHF. We know from LHF that interfering with this process, such as by inhibiting angiotensin-converting enzyme or blocking b-blockade, is helpful in the long run. As a result, these drugs may be effective in the treatment of PAH. In addition, implantable cardioverter-defibrillators may minimise the risk of sudden cardiac death in PAH patients. Finally, pilot trials have shown that interventricular dyssynchrony, which is common in end-stage PAH, can benefit from cardiac resynchronization therapy.
Finally, treatments for LHF could be useful in the treatment of PAH. However, before they can be used to treat PAH, they must first be tested for safety and efficacy in well-designed clinical trials.
Keywords:
    Adrenergic b-antagonists artificial cardiac pacing implantable defibrillators pulmonary heart disease rennin-angiotensin system right ventricular dysfunction
  • PDF (436 K)
  • XML
(2022). Lessons from the left heart in developing novel therapeutic options for right heart failure in pulmonary arterial hypertension. European Journal of Molecular & Clinical Medicine, 9(3), 3309-3325.
1Nayan Kumar Patel, 2Rekha Manjhi, 3Sudarsan Pothal, 4Narendra, 5Pravati Dutta, 6Aurobindo Behera .. "Lessons from the left heart in developing novel therapeutic options for right heart failure in pulmonary arterial hypertension". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 3309-3325.
(2022). 'Lessons from the left heart in developing novel therapeutic options for right heart failure in pulmonary arterial hypertension', European Journal of Molecular & Clinical Medicine, 9(3), pp. 3309-3325.
Lessons from the left heart in developing novel therapeutic options for right heart failure in pulmonary arterial hypertension. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 3309-3325.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 56
  • PDF Download: 102
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus